Fresenius SE Cash Flow from Investing Activities 2016-2024 | FSNUY
Fresenius SE annual/quarterly cash flow from investing activities history and growth rate from 2016 to 2024. Cash flow from investing activities can be defined as the total change in cash resulting from a companies investments
- Fresenius SE cash flow from investing activities for the quarter ending September 30, 2024 was $-0.184B, a 87.87% decline year-over-year.
- Fresenius SE cash flow from investing activities for the twelve months ending September 30, 2024 was $-3.749B, a 32.49% decline year-over-year.
- Fresenius SE annual cash flow from investing activities for 2023 was $-3.449B, a 25.58% increase from 2022.
- Fresenius SE annual cash flow from investing activities for 2022 was $-2.747B, a 17.58% decline from 2021.
- Fresenius SE annual cash flow from investing activities for 2021 was $-3.333B, a 3.1% decline from 2020.
| Fresenius SE Annual Cash Flow Investing (Millions of US $) |
|
|---|---|
| 2023 | $-3,449 |
| 2022 | $-2,747 |
| 2021 | $-3,333 |
| 2020 | $-3,439 |
| 2019 | $-5,439 |
| 2018 | $-1,729 |
| 2017 | $-8,556 |
| 2016 | $-2,311 |
| 2015 | $-1,659 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Outpatient & Home Care | $21.804B | $24.011B |
| Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quest Diagnostics (DGX) | United States | $19.317B | 19.51 |
| DaVita (DVA) | United States | $11.363B | 14.49 |
| Encompass Health (EHC) | United States | $9.962B | 22.32 |
| Chemed (CHE) | United States | $8.236B | 25.31 |
| Elanco Animal Health (ELAN) | United States | $5.492B | 13.07 |
| Option Care Health (OPCH) | United States | $5.459B | 25.87 |
| RadNet (RDNT) | United States | $4.453B | 98.62 |
| Amedisys (AMED) | United States | $2.998B | 21.34 |
| LifeStance Health (LFST) | United States | $2.904B | 0.00 |
| Addus HomeCare (ADUS) | United States | $1.974B | 22.91 |
| Astrana Health (ASTH) | United States | $1.946B | 26.61 |
| U.S Physical Therapy (USPH) | United States | $1.298B | 34.13 |
| Pennant (PNTG) | United States | $0.864B | 34.93 |
| Aveanna Healthcare Holdings (AVAH) | United States | $0.799B | 0.00 |
| Atai Life Sciences (ATAI) | Germany | $0.305B | 0.00 |
| Bioqual (BIOQ) | United States | $0.054B | 0.00 |
| Daxor (DXR) | United States | $0.036B | 0.00 |
| Ontrak (OTRK) | United States | $0.007B | 0.00 |
| MEDIROM Healthcare Technologies (MRM) | Japan | $0.004B | 0.00 |
| IMAC Holdings (BACK) | United States | $0.001B | 0.00 |
| Psychemedics (PMD) | United States | $0.000B | 0.00 |